Results 11 to 20 of about 5,803 (182)

Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent.

PLoS ONE, 2015
Ledipasvir, a direct acting antiviral agent (DAA) targeting the Hepatitis C Virus NS5A protein, exhibits picomolar activity in replicon cells. While its mechanism of action is unclear, mutations that confer resistance to ledipasvir in HCV replicon cells ...
Hyock Joo Kwon, Weimei Xing, Katie Chan, Anita Niedziela-Majka, Katherine M Brendza, Thorsten Kirschberg, Darryl Kato, John O Link, Guofeng Cheng, Xiaohong Liu, Roman Sakowicz   +10 more
doaj   +2 more sources

New-Onset Diabetes Mellitus With Exposure to Ledipasvir and Sofosbuvir [PDF]

Journal of Investigative Medicine High Impact Case Reports, 2015
The combination therapy of ledipasvir/sofosbuvir was approved by the Food and Drug Administration in 2014 for the treatment of chronic hepatitis C. Although hyperglycemia is not well known to occur with its use, we present 2 cases of new-onset diabetes ...
Resmi Premji MD, Nira Roopnarinesingh MD, Nazia Qazi MD, Eric S Nylen MD   +3 more
doaj   +2 more sources

Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection

Infection and Drug Resistance, 2018
Ossama A Ahmed,1 Hany H Kaisar,1 Rehab Badawi,2 Nehad Hawash,2 Hossam Samir,1 Sherif ST Shabana,1 Mohamed Hassan A Fouad,1 Fatma H Rizk,3 Samy A Khodeir,4 Sherief Abd-Elsalam2 1Department of Internal Medicine, Faculty of Medicine, Ain Shams University ...
Ahmed OA, Kaisar HH, Badawi R, Hawash N, Samir H, Shabana SST, Fouad MHA, Rizk FH, Khodeir SA, Abd-Elsalam S   +9 more
doaj   +1 more source

Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective

Therapeutics and Clinical Risk Management, 2016
Marcel Nkuize,1 Thomas Sersté,1,2 Michel Buset,1 Jean-Pierre Mulkay11Department of Gastroenterology and Hepatology, Saint-Pierre University Hospital, 2Department of Gastroenterology, Pancreatology and Hepatology, Hôpital Academique Erasme ...
Nkuize M, Sersté T, Buset M, Mulkay JP
doaj   +1 more source

Acute Kidney Injury in Patients Undergoing Chronic Hepatitis C Virus Treatment With Ledipasvir/Sofosbuvir

Hepatology Communications, 2018
Ledipasvir‐sofosbuvir, a once‐a‐day, oral combination pill, was approved in 2014 for the treatment of chronic hepatitis C infection. Initial trials did not comment on nephrotoxicity; however, recent data suggest a risk of acute kidney injury (AKI) with ...
Patrick R. Brown, Omar Sadiq, Alexander Weick, Adrienne Lenhart, Mohammad Elbatta, Christopher Fernandez, Anas Kutait, Robert Pompa, Syed‐Mohammed Jafri   +8 more
doaj   +3 more sources

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. [PDF]

, 2017
BACKGROUND: In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of sustained virologic response among previously untreated patients with ...
Kwo, Paul Y., Agarwal, Kosh, Muir, Andrew J., Buti, Maria, Symonds, William T., Mo, Hongmei, Afdhal, Nezam, Jacobson, Ira M., Marcellin, Patrick, Romero-Gómez, Manuel, Pang, Philip S., Foster, Graham R., Mangia, Alessandra, Chojkier, Mario, Ding, Xiao, Yang, Jenny C., Zarski, Jean Pierre, Bräu, Norbert, Gitlin, Norman, Puoti, Massimo, Buggisch, Peter, Forns, Xavier, Subramanian, G.Mani, Zeuzem, Stefan, McHutchison, John G.   +24 more
core   +4 more sources

Metastasis of Hepatocellular Carcinoma to the Urinary Bladder: A Case Report and Literature Review. [PDF]

IJU Case Rep
ABSTRACT Introduction Although secondary bladder tumors from distant metastases are rare, those originating from hepatocellular carcinoma are particularly uncommon, with only a few cases reported to date. Case Presentation An 81 year old male with hepatocellular carcinoma developed a rapidly growing 23 mm‐sized bladder tumor during systemic therapy ...
Fukagawa E, Oka S, Sakaguchi K, Yamamoto S, Ikemura M, Akuta N, Urakami S.   +6 more
europepmc   +2 more sources

A Comprehensive Molecular and Clinical Investigation of Approved Anti-HCV Drugs Repurposing against SARS-CoV-2 Infection: A Glaring Gap between Benchside and Bedside Medicine

Vaccines, 2023
The limited availability of effective treatment against SARS-CoV-2 infection is a major challenge in managing COVID-19. This scenario has augmented the need for repurposing anti-virals for COVID-19 mitigation.
Sneha Bansode, Pawan Kumar Singh, Meenakshi Tellis, Anita Chugh, Narendra Deshmukh, Mahesh Gupta, Savita Verma, Ashok Giri, Mahesh Kulkarni, Rakesh Joshi, Dhruva Chaudhary   +10 more
doaj   +1 more source

Combined Use of Amentoflavone and Ledipasvir Could Interfere with Binding of Spike Glycoprotein of SARS-CoV-2 to ACE2: The Results of Molecular Docking Study [PDF]

, 2020
In this study we used molecular docking method to test 248 drugs related to the virus research against spike glycoprotein of SARS-CoV-2. For ten top-ranked drugs the binding sites and interactions with spike glycoprotein were analyzed in detail. The best-
Kateryna, Miroshnychenko, Anna, V. Shestopalova   +1 more
core   +2 more sources

Treatment of Chronic HCV Infection with Direct Acting Antivirals

Central Asian Journal of Medical Sciences, 2021
Objectives: This study was conducted to discover the treatment outcome and side effects of chronic hepatitis C virus patients treated with Direct-Acting Antivirals (DAAs).
Bekhbold Dashtseren, Zulkhuu Genden, Odgerel Oidovsambuu, Anir Enkhbat, Ganbolor Jargalsaikhan, Sumiya Byambabaatar, Myammarsuren Shagdarsuren, Altankhuu Murdorj, Oyungerel Ravjir, Naranbaatar Dashdorj, Naranjargal Dashdorj, Dagvadorj Yagaanbuyant, Batbaatar Gunchin   +12 more
doaj   +1 more source